Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02930681
Other study ID # INQ/024515
Secondary ID
Status Completed
Phase N/A
First received October 10, 2016
Last updated February 7, 2017
Start date August 2016
Est. completion date November 2016

Study information

Verified date February 2017
Source InQpharm Group
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Glucosanol had previously been proven to be effective in aiding weight loss and weight loss maintenance. Studies have also shown that Glucosanol (also known as Phaseolamin), was effective in aiding weight loss and also has evidence on reducing post-prandial glucose levels. This study is to enrich the existing evidence on dose-dependent post-prandial glucose effects of Glucosanol


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date November 2016
Est. primary completion date November 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Caucasian males and females, 18 to 65 years old

- Body mass index (BMI) 25.0-29.9 kg/m2

- Generally in good health

- Normal fasting blood glucose (FBG) 3.9- <5.6 mmol/L (70- <100 mg/dL) and glycated hemoglobin HbA1c of 4- <5.7 %

- Readiness to adhere to consumption of test meals and defined restrictions prior to test meals (refer to section 11.8 for details)

- Readiness to adhere to habitual lifestyle during the study, in particular to:

1. maintain the same level of physical activity during the study, including non-strenuous transportation to the study visits

2. if smoking, regular smoking at the same level as prior

- to the study and no smoking on days of test meals

- prior and during the visit

- Stable body weight in the last 3 months prior to V1 (=5% self-reported change)

- Stable concomitant medications (if any) for at least last 3 months prior to V1

- Women of child-bearing potential only:

1. negative pregnancy testing (ß-HCG in urine at V1)

2. commitment to use reliable contraception methods

Exclusion Criteria:

- Known sensitivity to any ingredients / excipients of the IP

- Known food allergy (e.g. to cow's milk, eggs, wheat, crustacean, nuts etc.)

- Clinically relevant excursions of safety parameters

- Digestion/absorption disorders in gastrointestinal (GI) tract (e.g. inflammatory bowel disease)

- Uncontrolled hypertension >140/90 mmHg at V1

- Uncontrolled thyroid disorder at V1

- Any serious condition or disease that renders subjects ineligible

- Change in daily dose of any treatment and/or use of supplements with a possible impact on glycemic control in the last 3 months prior to V1 and throughout the study (refer to section 10 for details)

- Use of any anti-diabetic treatment or use of treatment and/or supplementation, for reduction of blood glucose levels within the last 4 weeks before V1 and throughout the study

- Use of medications or dietary supplements that may influence body weight =4 weeks and gastrointestinal functions =2 weeks prior to V1 and during the study

- Antibiotic and cortisone therapy =2 weeks prior to V1 and during the study

- Vegetarians and subjects with self-reported diet high in fat or protein

- Strenuous exercise within one day prior to each blood glucose sampling (including V1)

- History of bariatric surgery, small bowel resection or extensive bowel resection

- Recent blood donation within =1 month prior to study

- Alcohol abuse (men: =21 units/week, women: =14 units/ week; 1 unit equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits) and any alcohol consumption within 24 h before blood glucose sampling

- Inability to comply with study procedures

- Pregnancy or nursing

- Participation in another study during the last 30 days of the screening visit (V1)

- Any other reason deemed suitable for exclusion, per investigator's judgment

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Glucosanol 500mg

Placebo


Locations

Country Name City State
Germany analyze & realize GmbH Berlin

Sponsors (1)

Lead Sponsor Collaborator
InQpharm Group

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in total PPG between verum 1000mg and 2000mg study arms vs the placebo study arm Change defined as incremental AUC0 - AUC120min in mmol/(L*min) 120 mins
See also
  Status Clinical Trial Phase
Completed NCT01684332 - Postprandial Response to Different Jams N/A
Completed NCT03730727 - Exercise-meal Timing and Postprandial Glucose Control N/A
Completed NCT03242876 - The Effects of Citric and Malic Acid Found in Pomegranate Juice on Glycaemic Response to White Bread. N/A
Completed NCT05152745 - Effect of Ginger Extract on Postprandial Glycaemia of Healthy Adults and Its Antioxidant Properties N/A
Terminated NCT04298710 - Effects of Arm Cycling and Leg Cycling on Postprandial Blood Glucose Levels in Healthy Persons N/A
Recruiting NCT06444984 - The Movie Theater Study N/A
Enrolling by invitation NCT02488018 - Investigation of the Glycemic Index of Ethiopian Honey Phase 0
Completed NCT04655131 - Effect of Protein Intake on Post Prandial Hyperglycemia in Children and Adolescents With Type1 Diabetes Mellitus N/A
Completed NCT04914416 - Evaluation of OxxyneaGS in Acute Glycemic Regulation on Light Hyperglycemic Subjects N/A
Recruiting NCT05774613 - Effect of Hibiscus Sabdariffa Beverage N/A
Completed NCT02621307 - Effect of Salba & Flax on Postprandial Glycemia and Subjective Satiety Phase 1
Completed NCT05140629 - Effect of Baobab Fruit on Postprandial Glycaemia in Healthy Adults N/A
Completed NCT03817749 - Ketone Supplementation, Glucose Control, and Cardiovascular Function N/A
Completed NCT04163874 - Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial Pancreas N/A
Terminated NCT04079881 - Glucagon Response to Prandial Insulin Administration in Persons With Type 1 Diabetes Phase 1/Phase 2
Recruiting NCT06241976 - Diabetes Risk in East London and Its Association With Vitamin D by Ethnic Group (DELVE) N/A
Active, not recruiting NCT04730882 - Effect of Postprandial Hyperglycemia on Vasculature in Type 1 Diabetes and Healthy Adults
Completed NCT05528874 - NUTRACORE, Glycaemic Index and Appetite N/A
Recruiting NCT03255876 - Effects of Enriched Fruit Juice on Blood Glucose Levels After a Meal in Healthy Subjects N/A